International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

# Artificial Intelligence in Cancer Diagnosis: Current Applications and Future Perspectives

**Dr. Karthik Reddy[1], Mrs. Priya Nair[2], Dr. Sandeep Patil[3], Miss. Aditi Joshi[4], Dr. Vivek Menon[5]**

[1]Associate Professor School of Pharmaceutical Sciences, Green Valley University, Hyderabad, India. drkarthikreddy.pharm@gmail.com
[2]Professor Department of Pharmaceutics, Green Valley University, Hyderabad, India. priyanair.research@gmail.com
[3]Professor Department of Pharmacognosy, Green Valley University, Hyderabad, India. dr.sandeep.patil.lab@gmail.com
[4]Assistant Professor Department of Pharmaceutical Analysis, Green Valley University, Hyderabad, India. aditijoshi.academics@gmail.com
[5]Professor Department of Pharmacology, Green Valley University, Hyderabad, India. vivekmenon.pharma@gmail.com

## ABSTRACT

Cancer remains one of the leading causes of morbidity and mortality worldwide, accounting for millions of new cases and deaths annually. Despite substantial progress in molecular biology, imaging technologies, and targeted therapeutics, early and accurate cancer diagnosis continues to represent a major clinical challenge due to tumor heterogeneity, overlapping pathological characteristics, and variations in disease progression. Delayed diagnosis often results in advanced-stage disease, reduced treatment efficacy, and poorer patient outcomes. Recent advances in artificial intelligence (AI) have transformed the diagnostic landscape by enabling automated analysis of complex biomedical data with unprecedented speed and accuracy. Machine learning, deep learning, natural language processing, computer vision, and multimodal AI systems are increasingly being integrated into oncology to support cancer detection, classification, prognostic assessment, and clinical decision-making. These technologies facilitate the interpretation of radiological images, digital pathology slides, genomic profiles, liquid biopsy data, and electronic health records, providing comprehensive diagnostic insights beyond conventional analytical approaches. AI-assisted diagnostic systems have demonstrated remarkable performance across multiple malignancies, including breast, lung, colorectal, prostate, liver, brain, and skin cancers, while also improving workflow efficiency and reducing interobserver variability. Furthermore, emerging multimodal models capable of integrating imaging, molecular, and clinical information are paving the way toward highly personalized cancer diagnosis. Nevertheless, important challenges remain, including algorithmic bias, limited interpretability, data privacy concerns, regulatory approval, and clinical validation across diverse patient populations. This review discusses the current applications of artificial intelligence in cancer diagnosis, highlights recent technological advances, examines existing limitations, and explores future perspectives for AI-driven precision oncology.

**Keywords:** *Artificial intelligence, Cancer diagnosis, Deep learning, Machine learning, Digital pathology, Medical imaging, Precision oncology, Radiomics, Histopathology, Clinical decision support.*

**Article History**
**Received:** 10 June 2026; **Accepted:** 15 June 2026; **Published:** 25 June 2026

**Citation**
Reddy. K., (2026). Artificial Intelligence in Cancer Diagnosis: Current Applications and Future Perspectives. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS), 2(6), 78-85*
**DOI:** https://doi.org/10.65477/2026.v.2i.6.08



## 1. Introduction

Cancer is a multifactorial disease characterized by uncontrolled cellular proliferation, genomic instability, metabolic reprogramming, immune evasion, and extensive biological heterogeneity. The complexity of tumor biology presents significant challenges for timely diagnosis, disease classification, and individualized therapeutic planning. Accurate diagnosis remains the cornerstone of effective oncology care because treatment selection, prognosis, and survival largely depend on identifying malignancies at their earliest stages [1].

Traditional cancer diagnosis relies on a combination of clinical examination, laboratory investigations, medical imaging, histopathological evaluation, molecular testing, and increasingly, genomic profiling. Although these diagnostic approaches have substantially improved patient care over recent decades, they are frequently limited by subjective interpretation, variability among clinicians, time-intensive workflows, and the inability to integrate the rapidly expanding volume of biomedical information generated during routine clinical practice [2].

The exponential growth of healthcare data has fundamentally changed modern oncology. High-resolution radiological imaging, whole-slide digital pathology, next-generation sequencing, transcriptomics, proteomics, metabolomics, and electronic health records collectively generate enormous quantities of structured and unstructured information that exceed the analytical capacity of conventional statistical methods. Consequently, healthcare systems require advanced computational tools capable of extracting clinically meaningful insights from these heterogeneous datasets [3].

Artificial intelligence has emerged as one of the most influential technological developments in modern medicine. AI refers to computational systems capable of performing tasks that traditionally require human intelligence, including learning, pattern recognition, reasoning, prediction, and decision-making. Within oncology, AI has rapidly evolved from simple statistical classifiers to sophisticated deep learning architectures capable of identifying complex biological patterns across diverse biomedical modalities [4].

The incorporation of AI into cancer diagnosis has significantly enhanced the interpretation of radiological images, pathology slides, molecular biomarkers, and clinical documentation. Machine learning algorithms identify hidden relationships within structured datasets, while deep neural networks automatically extract high-dimensional features directly from medical images without requiring manual engineering. These capabilities enable earlier cancer detection, improved diagnostic accuracy, reduced observer variability, and more efficient clinical workflows [5].

Recent advances have further expanded AI applications through multimodal learning systems capable of simultaneously analyzing radiology, pathology, genomics, laboratory findings, and clinical narratives. By integrating multiple sources of patient information, these systems generate more comprehensive diagnostic predictions than models based on a single data modality. Such approaches are increasingly supporting precision oncology by enabling individualized risk assessment and biologically informed clinical decision-making [6].

Despite these remarkable achievements, the integration of AI into routine oncology practice continues to face several challenges. Issues related to model transparency, algorithmic fairness, patient privacy, regulatory oversight, and prospective clinical validation remain important barriers to widespread implementation. Addressing these limitations will be essential for ensuring safe, equitable, and clinically reliable deployment of AI technologies across healthcare systems [7].

This review provides a comprehensive overview of the current applications of artificial intelligence in cancer diagnosis, discusses major technological advances across imaging and molecular diagnostics, examines translational challenges, and highlights future opportunities for AI-enabled precision oncology.

## 2. Evolution of Artificial Intelligence in Cancer Diagnosis

Artificial intelligence has undergone remarkable evolution during the past several decades, progressing from rule-based expert systems to sophisticated deep learning models capable of outperforming conventional analytical methods in numerous diagnostic tasks. Early applications in oncology relied primarily on statistical learning algorithms developed for relatively small and structured clinical datasets. Logistic regression, decision trees, naïve Bayes classifiers, support vector machines, and random forests represented the first generation of computational diagnostic tools used for cancer risk prediction and biomarker classification [8].

Although these traditional machine learning methods demonstrated encouraging performance in selected clinical scenarios, their dependence on manually engineered features limited their ability to capture the complex biological variability observed across different malignancies. Researchers were required to identify relevant imaging characteristics or molecular biomarkers before model development, restricting scalability and reducing diagnostic flexibility [9].

The emergence of deep learning fundamentally transformed cancer diagnostics by eliminating the need for handcrafted feature extraction. Artificial neural networks composed of multiple hidden layers became capable of learning hierarchical representations directly from raw biomedical data. Convolutional neural networks (CNNs) rapidly became the dominant architecture for medical image analysis because of their exceptional ability to identify spatial patterns associated with tumor morphology, tissue architecture, and imaging abnormalities [10].

CNN-based systems demonstrated diagnostic accuracy comparable to experienced specialists across several oncology disciplines. Automated detection of pulmonary nodules on computed tomography, classification of breast lesions on mammography, segmentation of brain tumors on magnetic resonance imaging, and recognition of melanoma from dermoscopic images all illustrated the tremendous potential of deep learning in clinical oncology [11].

More recently, transformer architectures and attention-based neural networks have introduced another major advancement in AI development. Unlike convolutional models that primarily focus on local image features, transformers capture long-range contextual relationships through self-attention mechanisms. This capability allows more comprehensive interpretation of large pathology slides, radiological images, genomic sequences, and clinical documents, substantially improving diagnostic performance across complex oncology datasets [12].

Simultaneously, natural language processing technologies have revolutionized the analysis of unstructured clinical information. Modern language models can automatically extract diagnostic findings, summarize pathology reports, identify relevant clinical histories, and assist physicians in interpreting rapidly expanding medical literature. These capabilities improve documentation efficiency while supporting evidence-based clinical decision-making [13].

The convergence of imaging AI, genomic analytics, language models, and multimodal learning has shifted oncology from isolated diagnostic algorithms toward integrated intelligent healthcare systems. Rather than analyzing individual datasets independently, contemporary AI platforms increasingly combine imaging, pathology, molecular biology, laboratory data, and electronic health records to provide comprehensive patient-specific diagnostic assessments [14].

This progression reflects a broader transformation within oncology toward precision medicine, where diagnostic decisions are informed by the integration of biological, clinical, and imaging information rather than isolated observations. Continued improvements in computational power, data availability, and algorithmic sophistication are expected to further expand AI applications across every stage of cancer diagnosis and management [15].

## 3. Major Artificial Intelligence Technologies Used in Cancer Diagnosis

Artificial intelligence encompasses a diverse collection of computational methodologies that contribute to modern cancer diagnosis. Each technology offers unique strengths depending on the clinical application, data modality, and diagnostic objective.

Machine learning remains one of the most widely applied AI approaches in oncology. Supervised learning algorithms are trained using labeled clinical datasets to distinguish malignant from benign lesions, predict disease progression, estimate recurrence risk, and classify molecular subtypes. Unsupervised learning techniques identify hidden biological patterns within complex datasets without predefined outcome labels, facilitating biomarker discovery and molecular subclassification [16].

Deep learning has become the dominant methodology for analyzing complex biomedical images. Deep neural networks automatically learn hierarchical imaging features associated with tumor morphology, vascular architecture, cellular organization, and tissue heterogeneity. Their ability to process raw imaging data without manual feature engineering has substantially improved diagnostic accuracy across radiology and pathology [17].

Computer vision technologies enable automated interpretation of medical images by identifying lesions, segmenting tumors, quantifying tissue characteristics, and measuring disease progression. These systems assist radiologists and pathologists by rapidly analyzing thousands of images while maintaining high diagnostic consistency [18].

Natural language processing has become increasingly valuable for extracting clinically relevant information from pathology reports, radiology reports, physician notes, discharge summaries, and scientific literature. Automated information extraction reduces documentation burden and facilitates clinical decision support by organizing large volumes of unstructured text into structured diagnostic knowledge [19].

Generative AI represents another emerging area with important implications for oncology. These models generate synthetic medical images, augment limited training datasets, simulate rare disease presentations, and assist researchers in developing robust diagnostic algorithms. Synthetic data generation may improve model generalizability while reducing challenges associated with limited annotated datasets [20].

The integration of these complementary AI technologies has established the foundation for increasingly sophisticated cancer diagnostic systems capable of supporting clinicians throughout the diagnostic pathway.

## 4. Artificial Intelligence in Medical Imaging for Cancer Diagnosis

Medical imaging plays a central role in cancer diagnosis, staging, treatment planning, and disease surveillance. Modalities such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound, mammography, and digital radiography generate enormous volumes of imaging data that require accurate interpretation by radiologists. Artificial intelligence has significantly enhanced this process by improving lesion detection, image segmentation, tumor characterization, and diagnostic consistency [21].

Deep learning algorithms, particularly convolutional neural networks, have demonstrated exceptional performance in recognizing subtle imaging abnormalities that may be overlooked during routine clinical evaluation. These systems automatically identify complex imaging features associated with tumor morphology, tissue heterogeneity, vascularity, necrosis, and metastatic spread. AI-assisted image analysis not only improves diagnostic sensitivity but also reduces interobserver variability among radiologists [22].

In breast cancer screening, AI has become an important adjunct to digital mammography. Computer-aided detection systems analyze mammographic images to identify suspicious masses, architectural distortion, and microcalcifications suggestive of early malignancy. Several studies have demonstrated that AI-assisted mammography improves cancer detection rates while reducing unnecessary biopsies and false-positive interpretations [23].

Lung cancer diagnosis has also benefited considerably from AI-based image analysis. Deep learning algorithms trained on thousands of chest CT scans can detect pulmonary nodules, estimate malignancy probability, assess tumor growth, and identify early-stage lung cancers with high diagnostic accuracy. Automated volumetric measurements further improve longitudinal monitoring of indeterminate pulmonary nodules [24].

Artificial intelligence has similarly enhanced brain tumor imaging. MRI-based deep learning models accurately classify gliomas, meningiomas, pituitary tumors, and metastatic brain lesions while simultaneously segmenting tumor boundaries for surgical planning and radiotherapy guidance. These automated systems reduce manual workload and improve reproducibility across institutions [25].

Prostate cancer diagnosis increasingly incorporates AI into multiparametric MRI interpretation. Machine learning algorithms identify suspicious lesions within the prostate gland, estimate tumor aggressiveness, and assist clinicians in determining optimal biopsy targets. Such systems improve detection of clinically significant disease while reducing unnecessary invasive procedures [26].

Liver, pancreatic, ovarian, colorectal, and head-and-neck cancers have likewise demonstrated substantial improvements through AI-assisted imaging. Automated segmentation algorithms provide rapid delineation of tumor boundaries, quantify disease burden, and monitor treatment response throughout the clinical course. Integration of serial imaging further enables longitudinal assessment of disease progression and therapeutic effectiveness [27].

Radiomics has emerged as one of the most important developments in AI-enabled medical imaging. Radiomics refers to the extraction of hundreds or thousands of quantitative imaging features describing tumor shape, texture, intensity, vascularity, and spatial organization. Machine learning algorithms analyze these high-dimensional features to identify imaging biomarkers associated with tumor biology, molecular alterations, prognosis, and therapeutic response [28].

Radiogenomics extends this concept by integrating imaging characteristics with genomic and molecular information. AI models identify relationships between radiological phenotypes and underlying genetic alterations, enabling non-invasive prediction of molecular biomarkers that traditionally require tissue biopsy. Radiogenomic approaches have demonstrated promising applications in glioblastoma, lung cancer, breast cancer, and hepatocellular carcinoma [29].

The combination of radiomics, radiogenomics, and deep learning has transformed medical imaging into a comprehensive source of quantitative biological information rather than a purely anatomical assessment. Continued advances in multimodal AI are expected to further strengthen imaging-based precision oncology in the coming years [30].

## 5. Artificial Intelligence in Digital Pathology

Digital pathology has become one of the fastest-growing applications of artificial intelligence in cancer diagnosis. The widespread adoption of whole-slide imaging has enabled conventional glass pathology slides to be digitized into ultra-high-resolution images suitable for computational analysis. These digital datasets provide an ideal platform for deep learning algorithms capable of identifying complex histopathological patterns associated with malignancy [31].

Traditional microscopic examination remains highly dependent on pathologist expertise and is subject to interobserver variability, especially when evaluating borderline lesions or grading tumors. Artificial intelligence addresses these limitations by providing standardized, reproducible, and objective analysis of tissue architecture, nuclear morphology, glandular organization, mitotic activity, and stromal characteristics [32].

Convolutional neural networks and vision transformer architectures have demonstrated remarkable accuracy in distinguishing benign from malignant tissues across numerous cancer types. Automated pathology systems are capable of classifying breast carcinoma, colorectal adenocarcinoma, lung adenocarcinoma, prostate cancer, melanoma, lymphoma, gastric cancer, and numerous other malignancies with performance approaching that of experienced pathologists [33].

Beyond simple tumor detection, AI assists in grading cancer severity by quantifying histological characteristics associated with tumor aggressiveness. Automated assessment of mitotic figures, nuclear pleomorphism, gland formation, necrosis, and lymphovascular invasion improves consistency in pathological reporting while reducing diagnostic variability [34].

One of the most promising developments involves molecular prediction directly from histopathological images. Deep learning models can infer clinically relevant molecular alterations such as EGFR mutations, KRAS mutations, HER2 amplification, microsatellite instability, BRAF mutations, and programmed death-ligand 1 (PD-L1) expression without additional molecular testing. These capabilities may reduce diagnostic costs while accelerating treatment selection in precision oncology [35].

Artificial intelligence also enables quantitative analysis of the tumor microenvironment. Algorithms identify immune cell infiltration, stromal composition, angiogenesis, fibrosis, and spatial interactions between malignant and non-malignant cells. Such analyses provide valuable prognostic information and improve prediction of immunotherapy responsiveness across multiple cancer types [36].

Multiple-instance learning has become particularly valuable in pathology because whole-slide images often contain billions of pixels. Rather than analyzing entire slides simultaneously, these models evaluate smaller image patches before integrating local information into slide-level diagnostic predictions. This strategy improves computational efficiency while maintaining excellent diagnostic performance [37].

Integration of pathology AI with radiology, genomics, and clinical information has further expanded its clinical utility. Multimodal pathology platforms combine tissue morphology with molecular biomarkers and imaging features to generate comprehensive diagnostic profiles that support individualized patient management [38].

Although digital pathology AI continues to demonstrate outstanding diagnostic accuracy, widespread clinical implementation requires standardized datasets, external validation, regulatory approval, and seamless integration into existing pathology workflows. Continued collaboration between computational scientists and pathologists will be essential for successful translation into routine oncology practice [39].

## 6. Artificial Intelligence in Liquid Biopsy and Molecular Diagnostics

Liquid biopsy has emerged as a minimally invasive diagnostic strategy capable of detecting circulating tumor DNA, circulating tumor cells, extracellular vesicles, circulating RNA, and tumor-derived proteins in peripheral blood. Artificial intelligence has substantially enhanced liquid biopsy by identifying complex molecular signatures associated with early cancer detection, disease progression, and therapeutic response [40].

Artificial intelligence algorithms can process large-scale molecular datasets generated from liquid biopsy technologies to identify subtle patterns that may not be

detectable using conventional statistical approaches. Machine learning models integrate circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating tumor RNA, exosomal biomarkers, methylation profiles, and protein signatures to improve the sensitivity and specificity of cancer detection [41].
Deep learning approaches have shown considerable promise in distinguishing cancer-derived molecular alterations from normal biological variation. These systems facilitate early diagnosis, detect minimal residual disease, monitor treatment response, and identify disease recurrence months before conventional imaging techniques reveal clinically detectable lesions. Such capabilities have significant implications for personalized cancer management and long-term patient surveillance [42].

AI-assisted molecular diagnostics have also improved mutation detection by analyzing high-throughput sequencing data. Advanced algorithms identify driver mutations, copy number variations, structural rearrangements, and epigenetic alterations that influence tumor initiation and progression. Automated interpretation of sequencing results reduces analytical complexity while accelerating clinical reporting and therapeutic decision-making [43].
The integration of liquid biopsy with imaging, pathology, and clinical information further enhances diagnostic performance. Multimodal AI systems combine circulating biomarkers with radiological findings and histopathological characteristics to generate comprehensive diagnostic models capable of identifying cancer at earlier stages and predicting disease behavior more accurately than individual diagnostic modalities alone [44].

## 7. Artificial Intelligence in Genomics and Multi-Omics Integration

The rapid advancement of next-generation sequencing technologies has generated unprecedented volumes of genomic, transcriptomic, proteomic, metabolomic, and epigenomic data. Artificial intelligence has become indispensable for analyzing these highly complex datasets and identifying clinically relevant biological patterns that support precision oncology [45].
Machine learning algorithms analyze genomic alterations associated with carcinogenesis, including single nucleotide variants, insertions and deletions, chromosomal abnormalities, gene expression profiles, and epigenetic modifications. These computational approaches enable molecular classification of tumors, prediction of disease prognosis, and identification of actionable therapeutic targets [46].
Transcriptomic analysis provides additional insight into gene expression patterns associated with tumor development and progression. AI models identify molecular signatures that distinguish aggressive tumors from indolent disease, predict metastatic potential, and estimate response to chemotherapy, targeted therapy, and immunotherapy. Such information enables clinicians to individualize treatment strategies according to the molecular characteristics of each patient’s cancer [47].
Proteomic and metabolomic analyses further expand the diagnostic landscape by characterizing protein expression, metabolic pathways, and cellular signaling networks involved in malignant transformation. Artificial intelligence integrates these complementary datasets to provide a more comprehensive understanding of tumor biology than any single molecular platform can achieve independently [48].
Single-cell sequencing technologies have further transformed cancer research by enabling analysis of individual tumor cells within heterogeneous tumor populations. AI algorithms identify distinct cellular subpopulations, characterize clonal evolution, and investigate mechanisms of drug resistance, immune escape, and metastatic dissemination. These findings provide valuable insights into tumor evolution and support the development of personalized therapeutic strategies [49].
The emergence of multi-omics integration represents one of the most significant advances in computational oncology. Rather than analyzing genomic, transcriptomic, proteomic, and metabolomic datasets separately, multimodal AI platforms combine these complementary data sources to generate comprehensive molecular profiles that improve diagnostic accuracy, prognostic assessment, and therapeutic selection [50].

## 8. Clinical Decision Support Systems in Cancer Diagnosis

Artificial intelligence increasingly supports clinicians through advanced clinical decision support systems that integrate diverse patient information into evidence-based diagnostic recommendations. These systems combine medical imaging, pathology reports, laboratory findings, molecular profiles, electronic health records, and published clinical evidence to assist physicians throughout the diagnostic process [51].
Machine learning models estimate cancer risk, prioritize high-risk patients for further investigation, recommend appropriate diagnostic pathways, and assist multidisciplinary tumor boards in evaluating complex clinical cases. AI-generated recommendations complement physician expertise rather than replacing clinical judgment, thereby improving consistency and efficiency in oncology practice [52].
Natural language processing has significantly enhanced clinical documentation by extracting relevant information from pathology reports, radiology reports, physician notes, and hospital records. Automated summarization, information retrieval, and evidence synthesis reduce administrative workload while improving communication among healthcare professionals [53].
Large language models are also emerging as valuable tools for literature review, guideline interpretation, patient education, and clinical workflow optimization. By rapidly synthesizing large volumes of scientific evidence, these systems support informed clinical decision-making and facilitate the implementation of precision medicine in routine practice [54].

## 9. Challenges, Future Perspectives, and Conclusion

Despite remarkable technological progress, several challenges continue to limit the widespread adoption of artificial intelligence in cancer diagnosis. One of the most significant concerns is algorithmic bias arising from non-representative training datasets. Models developed using limited demographic populations may perform inconsistently when applied to diverse ethnic, geographic, or socioeconomic groups, potentially contributing to healthcare disparities [55].

Model interpretability remains another important limitation. Many deep learning systems function as "black-box" algorithms, making it difficult for clinicians to understand the reasoning underlying individual predictions. The development of explainable AI techniques, including attention maps, saliency visualization, SHAP analysis, and interpretable neural networks, is expected to improve transparency, clinician confidence, and regulatory acceptance [56].

Patient privacy, cybersecurity, and regulatory compliance also require careful consideration. Federated learning, privacy-preserving machine learning, differential privacy, and secure data-sharing frameworks are increasingly being adopted to facilitate collaborative AI development while protecting sensitive patient information. Robust governance frameworks will be essential to ensure ethical implementation of AI technologies across healthcare systems [57].

Future research is expected to focus on multimodal foundation models capable of simultaneously integrating radiology, pathology, genomics, liquid biopsy, electronic health records, and real-time physiological monitoring. Such comprehensive AI ecosystems may support continuous disease surveillance, adaptive diagnostic strategies, and highly individualized precision oncology. Digital twins, generative AI, and autonomous clinical decision-support systems are also anticipated to play increasingly important roles in next-generation cancer diagnosis [58].

As computational methodologies continue to evolve, successful clinical implementation will depend upon prospective validation, multicenter collaboration, standardized reporting, regulatory oversight, and close cooperation between clinicians, data scientists, engineers, and policymakers. Establishing internationally accepted standards for AI development and evaluation will be critical for ensuring safe, equitable, and reliable integration into clinical oncology practice [59].

## Conclusion

Artificial intelligence is transforming cancer diagnosis by enabling rapid, accurate, and data-driven interpretation of complex biomedical information. Applications spanning medical imaging, digital pathology, liquid biopsy, genomics, multi-omics integration, and clinical decision support have demonstrated considerable potential to improve early detection, diagnostic precision, molecular characterization, and personalized patient care. Although important challenges related to interpretability, bias, privacy, and clinical validation remain, continued advances in machine learning, deep learning, multimodal AI, and explainable artificial intelligence are expected to further strengthen the role of AI in oncology. With ongoing technological innovation and responsible clinical implementation, artificial intelligence is poised to become an indispensable component of future cancer diagnosis and precision medicine, ultimately improving patient outcomes and advancing the global standard of cancer care [60].

## References


1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
2. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
3. Kumar RMH. Childhood-Oncology Intelligence for Predicting Cancer Emergence, Optimizing Precision Therapies, and Simulating Lifelong Outcomes in Pediatric Malignancies Using Autonomous Foundation Models. Int J Drug Deliv Technol.2026;16(65s):162-173.DOI:10.25258/ijddt.16.65s.19
4. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881-4.
5. Rajendran LKK. Hematological Malignancy Identification via K-means based ROI Extraction. International Journal of Clinical Research in Medical Sciences. 2026;1(2):1-10. Doi:10.67231/kt1w3e73.
6. Maradi Hemanth Kumar R. Dynamic Digital Twins in Oncology: Foundation AI Models for Real-Time Predictive and Personalized Cancer Care. Power System Protection and Control. 2025;53(4):549-563. Doi:10.46121/pspc.53.4.38.
7. Kumar RMH. Pan-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models. Power System Protection and Control. 2023;51(4):92-100. Doi:10.46121/pspc.51.4.8.
8. Rajendran LKK. Identifying Determinants of Outcome in Post-Radiotherapy Cervical Carcinoma Requiring Adjuvant Surgery. International Journal of Clinical Research in Medical Sciences. 2026;1(2):1-10. Doi:10.67231/3acej759.
9. Maradi Hemanth Kumar R. AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology. Power System Protection and Control. 2023;51(4):66-83. Doi:10.46121/pspc.51.4.7.
10. Rajendran LKK. Machine Learning–Driven Symptom-Based Cancer Risk Stratification:A Systematic Review of Clinical Prediction Models and Methodological Rigor. Int J Drug Deliv Technol. 2026;16(40s):242-253.Doi:10.25258/ijddt.16.40s.26.
11. Kumar RMH. Maternal–Fetal Oncology Intelligence: Self-Evolving Foundation Models and Digital Twin Ecosystems for Precision Cancer Prediction, Treatment Optimization, and Maternal–Fetal Outcome Forecasting. Int J Drug Deliv Technol. 2026;16(65s):174-185. DOI: 10.25258/ijddt.16.65s.20
12. Rajendran OK. Bias, Fairness, and Ethical Challenges in Artificial Intelligence: A Comprehensive Review of Causes, Impacts, and Mitigation Strategies. Scientific Culture.

2026;12(2.1):13001-13010. Doi:10.5281/zenodo.20374091.
13. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. Doi:10.1038/s41591-018-0300-7.
14. Kumar RMH. Precision Oncofertility: Integrating Genomics, Reproductive Biomarkers, Treatment Toxicity Profiles, and Foundation Models for Fertility Preservation in Men and Women with Cancer. Int J Drug Deliv Technol. 2026;16(65s):186-200. DOI: 10.25258/ijddt.16.65s.21
15. Rajendran OK. Clinical Translation of Artificial Intelligence in Oncology: Real-World Validation, Workflow Integration, and Precision Medicine Applications. Int J Drug Deliv Technol. 2026;16(49s):956-964. Doi:10.25258/ijddt.16.49s.110.
16. Rajendran LKK. Interpretable Machine Learning for Early Mortality Prediction in Acute Myeloid Leukemia: A Decision Tree–Based Retrospective Cohort Study. Int J Drug Deliv Technol. 2026;16(40s):231-241.Doi:10.25258/ijddt.16.40s.25.
17. Kumar RMH. Self-Evolving Digital Twin Ecosystems for Early Detection and Precision Management of Breast, Lung, Colorectal, and Ovarian Cancers. Int J Drug Deliv Technol. 2026;16(65s):201-212. DOI: 10.25258/ijddt.16.65s.22
18. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–29. Doi:10.1038/s41591-018-0316-z.
19. Rajendran OK. Generative AI for Synthetic Medical Image Generation in Oncology: Addressing Data Scarcity in AI-Driven Cancer Diagnosis. Int J Drug Deliv Technol. 2026;16(49s):1010-1016. Doi:10.25258/ijddt.16.49s.117.
20. Rajendran LKK. Integrated Prognostic Modeling of Tumor Stage, Multimodal Therapy, and Functional Status in Lung Cancer Survival: A Real-World Cohort Study. Scientific Culture. 2026;12(5):567-576. Doi: 10.5281/zenodo.20738481.
21. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
22. Rajendran LKK. Integrative Pharmacogenomic Analysis of Drug Response Heterogeneity Across Cancer Cell Lines: Insights From Large-Scale GDSC Data. Scientific Culture. 2026;12(4):7537-7546. Doi:10.5281/zenodo.20767386.
23. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. J Intern Med. 2020;288(1):62–81. Doi:10.1111/joim.13030.
24. Rajendran OK. Tumor Microenvironment Interaction-Guided Graph Neural Networks for Survival Prediction from Whole-Slide Pathology Images. Int J Drug Deliv Technol. 2026;16(49s):481-488. Doi:10.25258/ijddt.16.49s.50.
25. Rajendran LKK. Evaluating the Association of Cancer-Related Risk Factors With Multisystem Health: Insights Into Fertility, Cardiovascular, and Renal Indicators. Scientific Culture. 2026;12(4):7520-7527.Doi:10.5281/zenodo.20767374.
26. Rajendran LKK. From Prediction to Precision: An Externally Validated Deep Learning–Based Survival and Adjuvant Therapy Recommendation System for Resected Stage III Non–Small Cell Lung Cancer. Int J Drug Deliv Technol. 2026;16(30s):430-438.doi:10.25258/ijddt.16.30s.41.
27. Kumar RMH. Multimodal foundation AI models in precision oncology: Integrating radiomics, pathomics, multi-omics, and clinical intelligence systems. Power System Protection and Control. 2024;52(4):189-204. Doi:10.46121/pspc.52.4.16.
28. Rajendran LKK. From Prediction to Practice: A Machine Learning–Based Clinical Decision Support Tool for Bevacizumab Risk Stratification in Oncology. Int J Drug Deliv Technol. 2026;16(30s):414-429. Doi:10.25258/ijddt.16.30s.40.
29. Rajendran OK. Self-supervised multimodal Learning for early cancer detection across Imaging and genomics. Power System Protection and Control. 2024;52(4):167-178. Doi:10.46121/pspc.52.4.14.
30. Rajendran OK. Explainable AI-Driven Clinical. Decision Support Systems in Precision Oncology:Interpretable Models for Multimodal Cancer Care. Scientific Culture. 2026;12(2.1):12359-12369. Doi:10.5281/zenodo.20328194.
31. Rajendran LKK. Impact of Treatment Modalities on Fertility, Sexual Function, and Psychological Outcomes in Testicular Cancer Survivors: A Comprehensive Review. Int J Drug Deliv Technol. 2026;16(30s):447-453. Doi:10.25258/ijddt.16.30s.43.
32. Rajendran LKK. Intelligent Omics-Driven Patient Stratification for Cancer Therapeutic Re-profiling. International Journal of Clinical Research in Medical Sciences. 2026;1(1):1-11. Doi:10.67231/gv5hck05.
33. Rajendran LKK. Cancer nanomedicine: utilizing the enhanced permeability and retention (EPR) effect to deliver high payloads of chemotherapeutic agents directly to tumor sites. Power System Protection and Control. 2024;52(2):123-129. Doi:10.46121/pspc.52.2.12.
34. Kather JN, Calderaro J. Development of AI in digital pathology. Nat Rev Clin Oncol. 2020;17(10):591–595. Doi:10.1038/s41571-020-00431-0.
35. Rajendran OK. AI-based radiogenomic Models for predicting immunotherapy response In solid tumors. Power System Protection and Control. 2023;51(4):24-37. Doi:10.46121/pspc.51.4.4.
36. Rajendran LKK. Enhanced Predictive Analytics for Early Malignancy Discovery in Routine Screening. International Journal of Clinical Research in Medical Sciences. 2026;1(1):1-10. Doi:10.67231/grams870.
37. Rajendran OK. Machine Learning-Based Prediction of Chemotherapy Toxicity in Colorectal Cancer: A Personalized Risk Stratification Approach.

Scientific Culture. 2026;12(5.1):942-952. Doi:10.5281/zenodo.20767359.
38. Rajendran OK. Federated radiology AI Models for multi-institutional cancer diagnosis Without data sharing. Power System Protection And Control. 2023;51(4):38-54. Doi:10.46121/pspc.51.4.5.
39. Kumar RMH. AI-augmented immuno-oncology: Foundation models for predicting immune response, resistance, and precision immunotherapy. Power System Protection and Control. 2024;52(2):193-208. Doi:10.46121/pspc.52.2.18.
40. Rajendran OK. Deep Reinforcement Learning in Oncology: Advances in Cancer Imaging, Radiotherapy, and Personalized Treatment. Scientific Culture. 2026;12(5):597-606. Doi:10.5281/zenodo.20767337.
41. Rajendran OK. DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING. Power System Protection and Control. 2025;53(3):313-328. Doi:10.46121/pspc.53.3.21.
42. Lu MY, Chen TY, Williamson DFK, et al. AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021;594(7861):106–110. Doi:10.1038/s41586-021-03512-4.
43. Rajendran OK. Artificial Intelligence in Oncologic Imaging: Deep Learning, Radiomics, and Clinical Integration for Precision Cancer Diagnosis. Int J Drug Deliv Technol. 2026;16(50s):871-880. Doi:10.25258/ijddt.16.50s.92.
44. Bilal M, Raza SEA, Azam A, et al. Development and validation of a weakly supervised deep learning framework to predict the risk of colorectal cancer recurrence from histology images. Lancet Oncol. 2021;22(11):153–163. Doi:10.1016/S1470-2045(21)00430-5.
45. Rajendran OK. DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA. Power System Protection and Control. 2025;53(4):486-501. Doi:10.46121/pspc.53.4.33.
46. Rajendran LKK. Genomic profiling: utilizing Multi-omics data to identify potential Therapeutic targets and resistance markers. Power System Protection and Control. 2024;52(4):159-166. Doi:10.46121/pspc.52.4.13.
47. Rajendran OK. Artificial Intelligence–Driven Multimodal Imaging for Cancer During Pregnancy: Advances in Maternal–Fetal Diagnostics and Precision Oncology. Int J Drug Deliv Technol. 2026;16(50s):862-870. Doi:10.25258/ijddt.16.50s.91.
48. Rajendran LKK. Immunotherapy and cell Therapy: developing CAR-T cell therapies and Other immune-based treatments for cancer and Autoimmune diseases. Power System Protection and Control. 2023;51(2):64-77. Doi:10.46121/pspc.51.2.7.
49. Rajendran OK. FOUNDATION MODEL–DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE. Power System Protection and Control. 2024;52(2):154-163. Doi:10.46121/pspc.52.2.14.
50. Rajendran LKK. Theranostics: integrating Diagnostic imaging agents and therapeutic Drugs into a single multifunctional nano-Platform for real-time monitoring of treatment. Power System Protection and Control.2025;53(2):376-386. Doi:10.46121/pspc.53.2.31.
51. Rajendran LKK. Mechanisms driving Immunotherapy resistance in colorectal cancer Liver metastases. Power System Protection and Control. 2024;52(1):29-37. Doi:10.46121/pspc.52.1.5.
52. Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387. Doi:10.1098/rsif.2017.0387.
53. Litjens G, Kooi T, Bejnordi BE, et al. A survey on deep learning in medical image analysis. Med Image Anal. 2017;42:60–88. Doi:10.1016/j.media.2017.07.005.
54. Hemanth Kumar RM. Integrated Transcriptomic and 3 Learning Framework Identifies a Blood-Based Biomarker Signature for Anthracycline-Induced Cardiotoxicity in Juvenile Cancer Survivors. Int J Drug Deliv Technol. 2026;16(40s):219-230. Doi:10.25258/ijddt.16.40s.24.
55. Mobadersany P, Yousefi S, Amgad M, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proc Natl Acad Sci USA. 2018;115(13):E2970–E2979. Doi:10.1073/pnas.1717139115.
56. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–762. Doi:10.1038/nrclinonc.2017.141.
57. Azizi S, Mustafa B, Ryan F, et al. Big self-supervised models advance medical image classification. Nature. 2021;594(7864):104–110. Doi:10.1038/s41586-021-03476-6.
58. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
59. Rajendran OK. DeepDRA: A Deep Learning Framework for Drug Repurposing and Cancer Drug Response Prediction Using Multi-Omics Data. Scientific Culture. 2026;12(3):68-77. Doi:10.5281/zenodo.12326001.
60. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.